You are here
Fostering Meaningful Partnerships
PATIENTS INSPIRE PARTNERSHIPS
At Pfizer, we put patient insights at the center of how we discover, develop and deliver new medicines and vaccines. To that end we often seek insights directly from patients as well as from those who advocate for them and represent their needs. These insights are invaluable as we seek to validate and/or supplement our working understanding of the patient condition. We engage every sector of government, society and industry, often times partnering with our peers to ensure we are maximizing all healthcare related benefits to our patients.
DELIVERING ON OUR PROMISE
We believe medicines are among the most powerful tools for patients to cure, treat and prevent illness and disability. They can also help to reduce costs of other more costly medical interventions, providing long-term savings to healthcare systems. All patients should have appropriate access to the medicines their doctors prescribe. We’re forging partnerships across the entire healthcare system to make medicines more affordable and accessible.
Our work with our partners, including various governments and institutions, aims to provide tailored solutions that balance the long-term need for innovation with near-term government and payer budgets. Recognizing challenges with healthcare sustainability, we are actively exploring innovative approaches and new partnerships to transform the way Pfizer brings medicines and vaccines to market and to help enable a shift to value-based care. We recognize our responsibility to be part of the solution and aim to be a leader in the industry. Our aim is to evolve from transactional relationships to true partnerships with governments and payers, focusing on improving health and patient access.
We are also engaging differently with patients – who are becoming more involved in their care – to help them better manage their health and get the best outcomes. For example, Pfizer has several value-based agreements across different therapeutic areas with payers in the U.S. and is exploring others with a range of commercial and public payers. Value-based agreements align care in exactly the right way: around the patient, rather than pitting one stakeholder against another. They incentivize biopharma players to develop – and payers to reimburse – drugs that will have a meaningful impact on patients.
WORKING TOGETHER TO IMPROVE PATIENT LIVES
By partnering with stakeholders and patient groups we can broaden and accelerate our reach in discovering new and improved therapies and solutions for patients. These partnerships represent a wide range of objectives and insights to clinical research, creating novel funding models, influencing policy and access, and furthering advocacy-initiated guidance for regulatory submissions. Pfizer’s disease-specific partnerships have been diverse and have included: cystic fibrosis (nonclinical research); sickle cell disease (ethnographic research); lupus (preclinical research/disease understanding); lung cancer and liver diseases (clinical trial protocol and informed consent process insights); Duchenne muscular dystrophy (protocol design insights and benefit/risk assessment); and other rare diseases (novel funding partnerships).
The following examples show our ever-growing patient partnership connections, breakthroughs and broadening efforts to improve patient lives worldwide.
Tobacco-Free Cities, Georgia State University
Pfizer has partnered, through a charitable contribution, with Georgia State University to support the development of tobacco control policies in five cities in China, helping to protect over 70 million people. This program helps to prevent initiation of smoking, promote quitting, and eliminate exposure to second-hand smoke.
Patient Engagement in HTA, European Federation of Neurological Associations (EFNA)
Pfizer is partnering, through a grant, with EFNA in a project that aims to understand patient engagement in HTA submissions across selected neurological conditions in Europe. This initiative also involves capability-building workshops for national patient advocates.
Oncology Collaboration Patient Group Summit: A look back at a one-of-a-kind patient summit Advocacy and collaboration for cancer care
In September 2017, Pfizer invited patient group delegates from Central and Eastern Europe to a summit. The summit was designed to support patient organizations in the region to share best practices with one another and facilitate the opportunity to pose questions to oncology health and advocacy experts.
Żyjmy Zdrowo Foundation (ZZF)
Żyjmy Zdrowo Foundation: Pfizer has partnered and continues to partner with ZZF on a social MBC campaign in Poland. The campaign aims at raising public recognition of the specific needs of the patients suffering from metastatic breast cancer (MBC). Pfizer provided an educational grant for that purpose.
SPARC-ing Efforts for Change in Metastatic Breast Cancer
On World Cancer Day 2017, Pfizer Oncology and the Union for International Cancer Control (UICC) announced the second round of Seeding Progress and Resources for the Cancer Community (SPARC) grants totaling $500,000 to organizations around the world to help MBC patients globally. To date, there are 40 SPARC grant recipients in 19 countries participating in this first-of-its-kind public-private partnership.
Facing Life: Voices of Metastatic Breast Cancer Patients
In order to directly listen to the needs of women with MBC, Pfizer Oncology partnered with cancer care advocate, survivor, and photographer Carolyn Taylor, founder of Global Focus on Cancer. Carolyn traveled around the globe to photograph and interview more than 40 women with metastatic breast cancer in 12 countries.
The Road to a Better Normal: Breast cancer patients and survivors in the European Union workforce
More women are surviving early breast cancer or living longer with metastatic disease. These women need healthcare policies that support access to treatment in order to return to their normal lives. Pfizer Oncology partnered with the Economist Intelligence Unit to better understand how to improve policies and better address patient needs.
Cada Minuto Cuenta (Every Minute Counts)
To raise awareness, support patients, and address unmet needs, Pfizer partnered with 21 Latin American breast cancer advocacy organizations in an ongoing initiative called “Cada Minuto Cuenta (Every Minute Counts)." In Brazil, celebrities, cancer experts and athletes also supported the campaign, impacting 56 million Brazilians throughout the country.
Rare Cancers Australia (RCA)
Pfizer has partnered with Rare Cancers Australia (RCA), which is working on a regional patient advocacy Mentoring Project to empower the patient voice across Asia Pacific. The aim of the project is to develop a mentoring program that will empower patient advocacy organizations as they address disease awareness and broaden access to medicines.
Acute Leukemia Advocacy
Pfizer hosted acute leukemia advocacy advisory boards in 2015 and 2016 to better understand the patient experience and unmet needs of acute leukemia patients and caregivers. As a result of those meetings, Pfizer partnered with Patient Power in Europe to develop two acute leukemia video "health centers" that include 88 videos featuring experts explaining AML and ALL. A subsequent version of the hub, launched in 2017, augmented the video library with perspectives from both patients and caregivers.
Annual Meeting for Hematology Patient Advocates
In December 2017, Pfizer organized the seventh annual meeting for hematology patient advocates at the American Society of Hematology congress. This is Pfizer’s largest annual global meeting for patient advocates, with more than 60 advocates attending in 2017. Feedback provided by the advocate attendees during roundtable sessions on patient/advocate involvement in clinical trials, patient reported outcomes, access, and therapy management has resulted in various projects and initiatives that will incorporate the insight we received and seek feedback from the leukemia and lymphoma community on an ongoing basis.
International Assistance Policy and Procedure (also known as Max Access Solution)
In 2015, Pfizer began a collaboration with The Max Foundation, launching a pilot procedure to handle requests for cancer medicines for uninsured and underinsured kidney cancer and gastrointestinal stromal tumor (GIST) patients living in lower-income economies outside of the U.S. where significant access hurdles exist. In 2017, the program was expanded to include additional oncology medicines for chronic myeloid leukemia, kidney cancer and lung cancer. Since the program’s initiation, more than 100 cancer patients living in 14 low-income or lower-middle-income countries have been able to access ongoing treatment for free through the program. Pfizer is continuing to work with The Max Foundation to find ways to get our products to cancer patients who need them in lower-income economies.
Kidney Cancer Advocacy Steering Committee
In 2017, Pfizer created a global Kidney Cancer Advocacy Steering Committee in order to support ongoing engagement with kidney cancer advocacy leaders and integrate the patient voice into Pfizer’s kidney cancer research, activities and initiatives. The steering committee includes six kidney cancer patient advocates from five countries and two kidney cancer-focused healthcare providers who meet (virtually) with Pfizer colleagues on a regular basis. The steering committee members help Pfizer to understand the unmet needs and preferences of kidney cancer patients; collaborate with the company to evaluate, develop or support possible resources, activities and tools that could help patients; and receive updates on Pfizer’s commitment to kidney cancer and ongoing research. Outputs of the steering committee include a jointly authored poster presented at the American Society of Clinical Oncology Genito-urinary annual congress in February 2018, and the creation of a conversation tool to help patients discuss post-nephrectomy care with their doctors.
NCDs, including cardiovascular disease, cancer, chronic respiratory disease, and diabetes are responsible for the largest percentage of global morbidity and mortality (38 million deaths annually). The growing burden of NCDs, particularly in low-resource settings, is a huge concern. Eighty percent of NCD-related deaths take place in low and middle-income countries, and if the rise in NCDs is not reversed, we risk losing progress in health and economic development. As a result, Pfizer, along with 22 other pharmaceutical companies in partnership with IFPMA, the World Bank and UICC, decided to launch Access Accelerated, a first-of-its-kind, multi-stakeholder collaboration focused on improving NCD care. Our goal of Access Accelerated is to help achieve the U.N. Sustainable Development Goals, and, in particular, reduce premature deaths from NCDs by one-third by 2030. All the companies involved commit to doing more individually by scaling up existing programs or developing new programs to address access to NCD medicines and care.
The European Federation of Crohn's and Ulcerative Colitis Association (EFCCA)
Pfizer partners with EFCCA to improve the public and policy maker understanding of the socio-economic impact of Crohn’s and colitis disease. EFCCA is a lead partner in Pfizer’s UC Narrative – a global patient and physician survey aimed at developing solutions that change treatment expectations, break down communication barriers and improve disease management.
Enabling early drug discovery and development with the Friedreich’s Ataxia Community
Pfizer is collaborating with the Friedreich’s Ataxia Research Alliance (FARA) to enable future clinical development programs for individuals and families with Friedreich’s Ataxia.
Clinical trials for Duchenne muscular dystrophy (DMD)
Pfizer is collaborating with Parent Project Muscular Dystrophy (PPMD) to optimize both the external landscape for clinical drug development broadly and our internal DMD clinical development programs.
The Economist Intelligence Unit (EIU): Stroke is 80% preventable, partnering to drive action!
To better understand barriers to earlier detection of risks for stroke, Pfizer partnered with The Economist Intelligence Unit (EIU) to investigate stroke prevention policies in 20 countries. That knowledge then informed a comprehensive campaign to mobilize critical stakeholders and disseminate a call to action to improve detection of AFib—a major risk factor for stroke. High-profile experts and executives from international medical and patient organizations were involved. Through social media, we, along with EIU and at least 17 participating advocacy organizations, reached more than 30,000 people.
Pfizer Patient Centricity Consultation Board
Pfizer held a meeting with 15 highly experienced Worldwide Patient Organizations in New York in October 2017 to share our Patient Centricity strategy and the efforts the company is producing to put the patient first. The Consultation Board participants have provided feedback that this is among the best kind of partnerships as it is a real opportunity to see into a company without filters and for advocates to provide insights.
Stronger Together Against RA
Given the absence of a global patient RA advocacy group, which limits the ability of RA patient groups around the world to collaborate on common issues, Pfizer established the “Stronger Together Against RA” initiative in 2013: a two-day forum for RA patient advocacy groups focused on the key issues facing RA patients in their region. In 2017, Pfizer hosted the fourth Stronger Together forum, bringing together almost 30 groups from across the greater European region to develop a series of tools and resources to empower patients in their conversations with their physicians – a key barrier in achieving optimal outcomes. This year, Pfizer is expanding the summit to Latin America, bringing over 30 groups from across the region.
Rare Disease Latin America Collaboration
Pfizer has built a sustained collaborative network of umbrella rare disease organizations from across the Latin America region since 2015. A large focus for the group has been to identify challenges, opportunities and solutions for improved access to early diagnosis, treatment and care and to build a framework for continued, sustainable collaboration among the rare disease community in the region. The network meets on a quarterly basis to review current progress, assess regional opportunities to raise rare diseases on the political agenda and share best practices across the organizations. The network has developed into a prominent advocacy movement across the region, with new efforts to support rare diseases as part of the discussions on universal health coverage.
Putting Patients First
Patients are at the center of what we do.